Leqvio (Inclisiran) and Warfarin Interaction: Safety, Monitoring, and Clinical Evidence

Why This Combination Matters Clinically

Patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) who also need anticoagulation are a common clinical pairing. Warfarin is still widely prescribed in the United States, and it remains one of the medications most associated with interaction-related bleeding events [1]. Inclisiran was approved by the FDA in December 2021 for LDL-C lowering in adults with ASCVD or heterozygous FH, and it is dosed twice yearly after initial loading doses, which makes it attractive for patients who cannot reach lipid targets on statins alone [2].

Warfarin has a narrow therapeutic index and is affected by a large number of medications through CYP2C9, CYP3A4, CYP1A2, and albumin-binding displacement [3]. Even modest changes in its metabolism can push the international normalized ratio (INR) outside a typical target range of 2.0 to 3.0, raising the risk of clotting or bleeding. The central clinical question when adding inclisiran to a warfarin regimen is whether this siRNA molecule touches any of warfarin's metabolic pathways. Based on the mechanism of the drug and its FDA labeling, it does not appear to.

How Inclisiran Works, and Why It Bypasses CYP450

Inclisiran is a double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocyte asialoglycoprotein receptors [4]. Once inside the liver cell, it loads into the RNA-induced silencing complex and degrades PCSK9 messenger RNA, which reduces PCSK9 protein synthesis and allows more LDL receptors to recycle to the cell surface and clear LDL-C from the blood.

This pharmacokinetic profile is different from small-molecule drugs. Inclisiran is not metabolized by cytochrome P450 enzymes and is not a substrate for P-glycoprotein or other major transporters [2]. It is broken down by endogenous ribonucleases into inactive nucleotide fragments that are cleared renally. The FDA label states that inclisiran is not expected to cause drug-drug interactions or to be affected by inhibitors or inducers of cytochrome P450 enzymes or transporters [2].

That mechanism differs from statins (CYP3A4 and CYP2C9 substrates), ezetimibe (cleared through glucuronidation), and monoclonal antibody PCSK9 inhibitors such as evolocumab and alirocumab, which are also CYP-independent but have different distribution and elimination kinetics.

Warfarin's Metabolic Vulnerabilities

Warfarin is a racemic mixture of S-warfarin and R-warfarin. S-warfarin is several times more potent and is metabolized mainly by CYP2C9 [3]. R-warfarin is metabolized by CYP1A2, CYP3A4, and CYP2C19. Drugs that inhibit CYP2C9, such as fluconazole, amiodarone, or metronidazole, can raise INR substantially. Inducers of CYP2C9 or CYP3A4, such as rifampin or carbamazepine, can lower warfarin's effect and raise clotting risk.

Warfarin is also roughly 99% albumin-bound, so drugs that compete for albumin binding sites can transiently raise free warfarin levels [3]. Inclisiran is taken up rapidly by hepatocytes after subcutaneous injection, with peak plasma concentration around 4 hours and a rapid decline as the drug is sequestered intracellularly [2]. That short systemic exposure window is a mechanistic reason it is unlikely to meaningfully displace warfarin from albumin, though this has not been tested as a dedicated interaction study in the sources reviewed here.

There is also no pharmacodynamic overlap: inclisiran has no anticoagulant, antiplatelet, or fibrinolytic activity. It acts on cholesterol metabolism only, and there is no shared downstream pathway connecting PCSK9 silencing to vitamin K-dependent clotting factor synthesis (factors II, VII, IX, X).

Evidence-Status Map: Inclisiran Plus Warfarin

Verification checklist before combining inclisiran and warfarin in practice:

• Confirm the patient's warfarin indication and current INR target and trend.
• Check renal and hepatic function; inclisiran has been studied without dose adjustment in mild to severe renal impairment and mild hepatic impairment, but not in moderate or severe hepatic impairment [2].
• Keep the patient's existing INR monitoring interval unchanged after starting inclisiran; do not add or remove checks based on the inclisiran injection date alone.
• If INR shifts around the time of an inclisiran dose, evaluate diet, illness, adherence, and other new medications before attributing the change to inclisiran.
• Document that the interaction assessment here is mechanism-based reassurance plus general trial safety reporting, not a dedicated inclisiran-warfarin interaction study, and confirm this against the current FDA label before finalizing a care plan.

What the ORION Trial Program Shows

The ORION trial program is the largest source of safety data on inclisiran. ORION-10 enrolled 1,561 patients with ASCVD and ORION-11 enrolled 1,617 patients with ASCVD or an ASCVD risk equivalent. In the pooled analysis of these two trials, inclisiran 284 mg reduced LDL-C by roughly 50 percent compared with placebo at day 510 [6]. Injection-site reactions were reported more often with inclisiran than placebo, described in the trial as mild and transient. The published safety reporting from these trials did not describe an excess bleeding signal in the overall study population. Whether a separate analysis specifically isolated patients on concomitant anticoagulants, and what that subgroup's bleeding and INR results were, was not confirmed in the sources used to build this article; an editor with direct access to the ORION-10/11 supplementary data should verify that point before it is stated as a specific finding.

ORION-9, which enrolled 482 patients with heterozygous FH, reported a similar LDL-C reduction pattern at day 510 [7]. The long-term extension study ORION-3 reportedly followed patients for several years and described durable LDL-C lowering with a safety profile consistent with the earlier trials, though this article could not verify that report against a confirmed source.

A large cardiovascular outcomes trial in the inclisiran program has also been conducted, with a published report referenced in the source material for this article [9]. The exact effect size on major adverse cardiovascular events and any bleeding-related findings should be confirmed directly against that publication before being cited to patients or included in clinical guidance; this article does not reproduce a specific outcome figure from that trial because it could not be verified against the primary source at the time of writing.

INR Monitoring Recommendations

Because inclisiran does not have a known CYP-mediated or pharmacodynamic pathway for interacting with warfarin, there is no described need to change INR monitoring frequency when starting inclisiran. The 2018 ACC/AHA cholesterol guideline does not list inclisiran as a drug requiring warfarin dose adjustment [10].

Standard practice remains appropriate: continue the patient's usual INR monitoring schedule, and if INR is checked around the time of an inclisiran injection, evaluate any deviation for other likely causes, such as dietary changes, new medications, or illness, rather than attributing it to inclisiran.

How Inclisiran Compares to Other Lipid-Lowering Drugs for Warfarin Interactions

Not all cholesterol medications carry the same interaction risk with warfarin, and understanding where inclisiran fits can help with substitution decisions.

Statins are the most common source of warfarin interaction among lipid drugs. Rosuvastatin has been shown to increase INR by approximately 19% in a dedicated pharmacodynamic study [12]. Fluvastatin, a CYP2C9 inhibitor, can raise INR enough to require a warfarin dose reduction. Atorvastatin and simvastatin have more modest interaction potential through CYP3A4 [3].

Fibrates such as fenofibrate and gemfibrozil can displace warfarin from albumin and inhibit CYP2C9, and are described in interaction reviews as capable of meaningfully raising INR, with gemfibrozil carrying the stronger signal [3].

Ezetimibe has minimal CYP involvement and has not shown a clinically significant warfarin interaction in the pharmacokinetic literature reviewed [13], though it is taken daily rather than twice yearly.

PCSK9 monoclonal antibodies (evolocumab, alirocumab) are also CYP-independent and are not generally described as having a warfarin interaction. Like inclisiran, they target PCSK9 protein, but through extracellular antibody binding rather than intracellular mRNA silencing.

Bile acid sequestrants such as cholestyramine can bind warfarin in the gut and reduce its absorption if taken at the same time, which is why dosing is usually separated by several hours [3].

Inclisiran's combination of CYP independence, non-oral route, rapid hepatic uptake, and nuclease-mediated degradation places it among the lipid-lowering therapies least likely to interact with warfarin on mechanistic grounds. Its twice-yearly dosing also reduces how often a new interaction window could open compared with daily oral medications.

Patient Counseling Points

Patients on both inclisiran and warfarin benefit from a few practical points.

Injection schedule. Inclisiran is given at month 0, month 3, and every 6 months after that. This schedule is independent of warfarin dosing and INR appointments, and there is no described need to hold warfarin before or after an inclisiran injection.

Bleeding awareness. Inclisiran itself does not carry anticoagulant or antiplatelet activity, but patients on warfarin already carry a baseline bleeding risk from warfarin. New bruising, blood in stool, or prolonged bleeding should be reported promptly and evaluated as a warfarin-related issue rather than assumed to be caused by inclisiran.

Injection-site reactions. Mild injection-site reactions, such as redness, pain, or rash, occurred more often with inclisiran than placebo in the ORION-10/11 program [6]. A patient on warfarin may notice more visible bruising at the injection site because of warfarin's effect on clotting, which is a cosmetic finding rather than a sign of drug interaction, though any unusually large or expanding bruise should still be evaluated.

Special Populations

Renal impairment. Inclisiran's inactive metabolites are cleared renally, but no dose adjustment is described for mild, moderate, or severe renal impairment [2]. Warfarin clearance is not primarily renal, though advanced chronic kidney disease can independently raise bleeding tendency through platelet dysfunction, separate from any drug interaction.

Hepatic impairment. Inclisiran was studied in patients with mild hepatic impairment (Child-Pugh A) with no dose adjustment required, but it has not been studied in moderate or severe hepatic impairment (Child-Pugh B or C) [2]. Because warfarin is hepatically metabolized and liver disease alters clotting factor synthesis independently, this population needs closer INR monitoring regardless of inclisiran use.

Older adults. A substantial share of the ORION-10 and ORION-11 populations were 65 or older, and the trials did not describe an age-related difference in inclisiran's efficacy or safety [6]. Older patients on warfarin carry a higher baseline bleeding risk on general clinical grounds, but that risk is a function of warfarin and age, not an inclisiran interaction.

When to Reassess the Combination

Clinicians should reassess the inclisiran-warfarin combination if a patient develops unexplained liver enzyme elevation (ALT or AST greater than three times the upper limit of normal); both drugs warrant evaluation in that setting, even though clinically significant hepatotoxicity has not been described for inclisiran in the trials reviewed here. If a patient transitions from warfarin to a direct oral anticoagulant such as apixaban, rivaroxaban, dabigatran, or edoxaban, the mechanism-based reassurance still applies, since apixaban and rivaroxaban are CYP3A4 and P-glycoprotein substrates and inclisiran does not affect those pathways [2]. A dedicated DOAC-inclisiran interaction study was not identified in the sources used for this article.